Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 349

1.
2.
3.

The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.

Whalen K, Miller S, Onge ES.

Clin Ther. 2015 Jun 1;37(6):1150-66. doi: 10.1016/j.clinthera.2015.03.004. Epub 2015 Apr 16. Review.

PMID:
25891804
4.

Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.

Scheen AJ.

Clin Pharmacokinet. 2015 Jul;54(7):691-708. doi: 10.1007/s40262-015-0264-4. Review.

PMID:
25805666
5.

The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.

Lajara R.

Expert Opin Pharmacother. 2014 Dec;15(17):2565-85. doi: 10.1517/14656566.2014.968551. Epub 2014 Oct 15. Review.

PMID:
25316597
6.

SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.

Scheen AJ.

Expert Opin Drug Saf. 2015;14(12):1879-904. doi: 10.1517/14740338.2015.1100167. Epub 2015 Oct 29. Review.

PMID:
26513131
7.

Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor.

Devineni D, Polidori D.

Clin Pharmacokinet. 2015 Oct;54(10):1027-41. doi: 10.1007/s40262-015-0285-z. Review.

PMID:
26041408
8.

Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations.

Scheen AJ.

Expert Opin Drug Metab Toxicol. 2014 May;10(5):647-63. doi: 10.1517/17425255.2014.873788. Epub 2014 Jan 3. Review.

PMID:
24387329
9.

Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.

Reed JW.

Vasc Health Risk Manag. 2016 Oct 27;12:393-405. eCollection 2016. Review.

10.

Update on developments with SGLT2 inhibitors in the management of type 2 diabetes.

Nauck MA.

Drug Des Devel Ther. 2014 Sep 11;8:1335-80. doi: 10.2147/DDDT.S50773. eCollection 2014. Review.

11.

SGLT2-inhibitors: a novel class for the treatment of type 2 diabetes introduction of SGLT2-inhibitors in clinical practice.

Cuypers J, Mathieu C, Benhalima K.

Acta Clin Belg. 2013 Jul-Aug;68(4):287-93. Review.

PMID:
24455799
12.

POTENTIAL PLACE OF SGLT2 INHIBITORS IN TREATMENT PARADIGMS FOR TYPE 2 DIABETES MELLITUS.

Handelsman Y.

Endocr Pract. 2015 Sep;21(9):1054-65. doi: 10.4158/EP15703.RA. Epub 2015 Jul 1. Review.

PMID:
26132997
13.

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes.

Brunton S, Reid TS.

Hosp Pract (1995). 2014 Aug;42(3):96-108. doi: 10.3810/hp.2014.08.1122. Review.

PMID:
25255411
14.

The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus.

Brunton SA.

Int J Clin Pract. 2015 Oct;69(10):1071-87. doi: 10.1111/ijcp.12675. Epub 2015 Jul 5. Review.

15.
16.

SGLT2 inhibitors in the treatment of type 2 diabetes.

Hasan FM, Alsahli M, Gerich JE.

Diabetes Res Clin Pract. 2014 Jun;104(3):297-322. doi: 10.1016/j.diabres.2014.02.014. Epub 2014 Mar 11. Review.

PMID:
24735709
17.

SGLT2 inhibition with dapagliflozin -- a novel approach for the management of type 2 diabetes.

Kilov G, Leow S, Thomas M.

Aust Fam Physician. 2013 Oct;42(10):706-10. Review.

18.

[SGLT2 inhibitors: a new therapeutic class for the treatment of type 2 diabetes mellitus].

Dagan A, Dagan B, SegaL G.

Harefuah. 2015 Mar;154(3):200-3, 210. Review. Hebrew.

PMID:
25962253
19.

Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.

Davidson JA, Kuritzky L.

Postgrad Med. 2014 Oct;126(6):33-48. doi: 10.3810/pgm.2014.10.2819. Review.

PMID:
25414933
20.

Empagliflozin for the treatment of Type 2 diabetes.

Gangadharan Komala M, Mather A.

Expert Rev Clin Pharmacol. 2014 May;7(3):271-9. doi: 10.1586/17512433.2014.908703. Epub 2014 Apr 9. Review.

PMID:
24716752

Supplemental Content

Support Center